Efficacy, Safety, and Predictors of Intradiscal Methylene Blue Injection for Discogenic Low Back Pain: Results of a Multicenter Prospective Clinical Series (2015)

Peer-Reviewed Study · Kallewaard JW, Geurts JW, Kessels A, et al. · March 6, 2015

Kallewaard JW et al., 2015-03-06: Prospective multicentre case series of intradiscal methylene blue in 15 patients, finding 40% with at least 30% pain relief at six months and no complications. Uncontrolled pilot that preceded the negative randomized trial.

Six months after the intervention, 40% of the patients claimed at least 30% pain relief. In patients who responded, physical function improved and medication use diminished. We observed no procedural complications or adverse events.

Kallewaard JW et al., 2015-03-06: Prospective multicentre case series of intradiscal methylene blue in 15 patients, finding 40% with at least 30% pain relief at six months and no complications. Uncontrolled pilot that preceded the negative randomized trial. Study type: prospective multicentre case series. N=15. Country: Netherlands. Intradiscal MB; dose not in abstract; single injection; 6-month follow-up. Funding/conflicts: not stated. Comparator: none (uncontrolled). Predictors of success: Pfirrmann grade 2 or less and better mental component score. The same group then ran the negative RCT. Study type: uncontrolled series.